



Inland Empire Health Plan

Drug Class Prior Authorization Criteria
Hereditary Angioedema

Line of Business: Medicaid

P & T Approval Date: August 5, 2022

Effective Date: September 2, 2022

These criteria have been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics Subcommittee.

Prior Authorization criteria is available for: Firazyr (icatibant), Haegarda (C1 esterase inhibitor)

FIRAZYR (icatibant)

Covered Uses:	Acute Hereditary Angioedema (HAE) attacks (Clinical Pharmacist review required)
Exclusion Criteria:	N/A
Required Medical Information:	Must meet all of the following requirements: a. C4 level below the lower limit of normal laboratory range b. Must meet "1" of the following requirements: 1. C1 inhibitor (C1-INH) antigenic level below the lower limit of normal laboratory range 2. C1-INH functional level below the lower limit of normal laboratory range 3. Documented C1-INH mutation
Age Restrictions:	Must be age of 18 years and older
Prescriber Restrictions:	Immunologist, Allergist, Hematologist
Other Criteria: requirement:	Reauthorization Criteria: Must meet "1" of the following a. Documentation of ongoing HAE attacks b. Documentation of clinical response to medication



Drug Class Prior Authorization Criteria
Hereditary Angioedema

HAEGARDA (C1 esterase inhibitor)

Covered Uses:	Routine prophylaxis of Hereditary Angioedema (HAE) attacks (Clinical Pharmacist review required)
Exclusion Criteria:	N/A
Required Medical Information:	Must meet all of the following requirements: <ul style="list-style-type: none">a. C4 level below the lower limit of normal laboratory rangeb. Must meet "1" of the following requirements:<ul style="list-style-type: none">1. C1 inhibitor (C1-INH) antigenic level below the lower limit of normal laboratory range2. C1-INH functional level below the lower limit of normal laboratory range3. Documented C1-INH mutationc. If indication is for prophylaxis (not acute attack): Documentation of inadequate response or clinically significant adverse effects to danazol
Age Restrictions:	Must be age of 12 years and older
Prescriber Restrictions:	Immunologist, Allergist, Hematologist
Other Criteria:	Reauthorization Criteria: Must meet the following requirement: <ul style="list-style-type: none">a. Documentation of clinical response to medication



Inland Empire Health Plan

Drug Class Prior Authorization Criteria
Hereditary Angioedema

Change Control		
Date	Change	RPH
06/23/2022	<ul style="list-style-type: none"> • Retired PA criteria for Medi-Cal Rx Benefits <ul style="list-style-type: none"> ○ Firazyr (icatibant) ○ Haegarda (C1 esterase inhibitor) 	NQ
08/06/2021	<ul style="list-style-type: none"> • Minor change in FIRAZYR reauthorization criteria (from “and” requirement to “or” requirement) • Retired documentation of frequency or laryngeal attack requirement in HAEGARDA criteria • Clarified indication applicable for trial and failure requirement of alternative in HAEGARDA criteria 	SV
08/28/2020	<ul style="list-style-type: none"> • Renewed with no changes 	RR
05/15/2019	<ul style="list-style-type: none"> • Added Firazyr and Haegarda to the formulary with PA • Retired criteria for non-formulary agents: Berinert, Kalbitor, Ruconest, Cinryze • Added age restrictions for Firazyr 	ND
06/29/2018	<ul style="list-style-type: none"> • Changed Format 	IK
05/16/2018	<ul style="list-style-type: none"> • Reformatted document • Added Haegarda that was previously reviewed under new drug review (NME) 	HC